Remikiren

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Remikiren
Remikiren.svg
Systematic (IUPAC) name
(2S)-2-[(2R)-2-benzyl-3-(2-methylpropane-2-sulfonyl)propanamido]-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-4-yl)propanamide
Clinical data
  • Investigational
Identifiers
126222-34-2 YesY
C09XA01
PubChem CID 6324659
DrugBank DB00212 YesY
ChemSpider 4884377 YesY
UNII LC7FBL96A4 YesY
KEGG D09038 YesY
ChEMBL CHEMBL31601 YesY
Chemical data
Formula C33H50N4O6S
630.839 g/mol
 YesY (what is this?)  (verify)

Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.[1]

References[edit]

  1. ^ Richter WF, Whitby BR, Chou RC (1996). "Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals". Xenobiotica 26 (3): 243–54. doi:10.3109/00498259609046705. PMID 8730917.